Dyadic International Inc (NASDAQ:DYAI) CEO Mark Emalfarb and CCO Matthew Jones tell Proactive's Andrew Scott the duo are in London for the Jefferies London Healthcare Conference, the biotech's third year attending.
Emalfarb and Jones say the Florida-based biotech is touting its recent collaboration with a leading animal health company, as well as its recent 3Q highlights. Dyadic will have a presence later this week at the Protein And Antibody Engineering Summit in Lisbon.
Price: 6.08 USD
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Dyadic International Inc named herein, including the promotion by the Company of Dyadic International Inc in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Director Interviews
Mining
Dyadic International Inc's (NASDAQ:DYAI) chief commercial officer Matthew Jones speaks to Proactive London during what's been a significant week for the company as it begins trading on Nasdaq. The Jupiter, Florida-based biotechnology platform company, engages in the development, and large...
Director Interviews
Full interview: Impax Asset Management reveals key themes...
Mining
Premier African CEO sees scope for greater stake in manganese mine...
Telecoms & Networks
Finance
